Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
66.74 USD | -3.02% | +2.84% | +21.04% |
Financials (USD)
Sales 2024 * | 541M | Sales 2025 * | 578M | Capitalization | 1.3B |
---|---|---|---|---|---|
Net income 2024 * | 33M | Net income 2025 * | 41M | EV / Sales 2024 * | 2.43 x |
Net Debt 2024 * | 20.98M | Net cash position 2025 * | 44.87M | EV / Sales 2025 * | 2.16 x |
P/E ratio 2024 * |
42.6
x | P/E ratio 2025 * |
27.8
x | Employees | 642 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.44% |
Latest transcript on ANI Pharmaceuticals, Inc.
1 day | -3.02% | ||
1 week | +2.84% | ||
Current month | +2.84% | ||
1 month | +1.31% | ||
3 months | -1.01% | ||
6 months | +36.37% | ||
Current year | +21.04% |
Managers | Title | Age | Since |
---|---|---|---|
Nikhil Lalwani
CEO | Chief Executive Officer | 46 | 20-09-07 |
Stephen Carey
DFI | Director of Finance/CFO | 53 | 16-05-05 |
Patrick Walsh
CHM | Chairman | 63 | 18-05-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Haughey
BRD | Director/Board Member | 60 | 18-04-30 |
Antonio Pera
BRD | Director/Board Member | 66 | 20-08-05 |
Patrick Walsh
CHM | Chairman | 63 | 18-05-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.95% | 11 M€ | -6.03% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 66.74 | -3.02% | 303,940 |
24-06-06 | 68.82 | +2.72% | 222,941 |
24-06-05 | 67 | +3.46% | 196,440 |
24-06-04 | 64.76 | +2.08% | 128,398 |
24-06-03 | 63.44 | -2.25% | 202,161 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.04% | 1.3B | |
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.62% | 248B | |
-2.04% | 219B | |
+10.97% | 216B | |
+5.90% | 164B | |
-0.73% | 162B |
- Stock Market
- Equities
- ANIP Stock